Loading...
•
Jun 30, 2024
Eton Q2 2024 Earnings Report
Eton Pharmaceuticals reported Q2 2024 results with product sales and royalty revenue increasing and NDA for ET-400 accepted by the FDA.
Key Takeaways
Eton Pharmaceuticals reported a net loss of $2.9 million, which includes a $2.0 million ET-400 filing fee. However, the company saw a 40% increase in product sales and royalty revenue compared to Q2 2023, reaching $9.1 million, driven by ALKINDI SPRINKLE and Carglumic Acid. The FDA accepted the NDA for ET-400 with a PDUFA date of February 28, 2025. The company generated $1.3 million in operating cash flow, including the payment of the one-time $2.0 million NDA filing fee for ET-400.
Product sales and royalty revenue reached $9.1 million, a 40% increase year-over-year.
ALKINDI SPRINKLE revenue grew 63% year-over-year.
NDA for ET-400 was accepted by the FDA with a PDUFA date of February 28, 2025.
The company generated $1.3 million in operating cash flow, including the $2.0 million ET-400 filing fee.
Revenue by Segment
Forward Guidance
Eton expects to continue to see sequential quarter-over-quarter growth of product sales through the remainder of 2024 and beyond. Eton anticipates initiating production of launch quantities in the fourth quarter of 2024, to allow for a commercial launch promptly after the expected approval.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...